In Plain English
Rather than injecting growth hormone, CJC-1295 asks your pituitary to release more of its own. That distinction matters: the body’s existing feedback controls stay in the loop, so release still follows a pulsatile pattern rather than the flat elevation that exogenous GH produces. The DAC version stays active for days; the non-DAC version produces a shorter, more natural pulse.
What people use it for. Raising growth hormone for body composition, recovery and sleep quality. It is almost always used with Ipamorelin rather than alone.
What to know before you buy. Make sure you know which version you are getting. The DAC version stays in your system for days and produces a sustained elevation; the non-DAC version clears in about half an hour and produces a pulse closer to what your body does naturally. Most current practice favours the non-DAC form, and that is what the blend uses. It reliably raises growth hormone; whether that translates into the results people want has not been demonstrated in proper trials.
What It's Used For
| Goal | What that rests on |
|---|---|
| Growth hormone support | Early-phase human pharmacokinetic studies confirm it raises GH and IGF-1 |
| Recovery and sleep quality | Commonly reported; consistent with GH's known physiological roles |
| Body composition | The reason most people use it, though outcome trials in healthy adults do not exist |
| Works with your own system | Prompts your pituitary rather than supplying GH directly, so natural feedback stays intact |
The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.
Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. Free shipping on every order, no minimum. Third-party COA available for every batch — HPLC purity and mass spec verification.
At a Glance
- Class
- Synthetic analogue of growth hormone releasing hormone (GHRH 1-29)
- Two versions
- With DAC — drug affinity complex extends half-life to several days. Without DAC (mod GRF 1-29) — short-acting, produces a pulse closer to natural release
- Mechanism
- Binds pituitary GHRH receptors, increasing endogenous growth hormone release rather than supplying GH directly
- Human data
- Early-phase pharmacokinetic and dose-escalation studies exist; no approved indication and no large outcome trials
- Regulatory (US)
- Not FDA-approved. Not on the July 2026 PCAC agenda
- Format
- Sold in a 5+5mg blend with Ipamorelin
Regulatory status
This compound was not on the July 2026 PCAC agenda. Its regulatory status is unchanged by that hearing, and reports about peptides being “cleared” in July 2026 do not apply to it. Treat its status as independent. CJC-1295 remains not FDA-approved and is not on the 503A bulks list.
DAC vs No DAC
| CJC-1295 with DAC | CJC-1295 no DAC (mod GRF 1-29) | |
|---|---|---|
| Half-life | Approximately 6-8 days | Approximately 30 minutes |
| GH pattern | Sustained elevation, or “bleed” | Sharp pulse, closer to physiological release |
| Typical use | Less frequent administration | Timed dosing, commonly at night |
| Main critique | Continuous elevation departs from natural pulsatility | Requires more frequent administration |
The non-DAC form is the more common choice in current practice and is what the CJC-1295 + Ipamorelin blend uses, on the reasoning that preserving pulsatility better reflects normal physiology.
Evidence Position
CJC-1295 has genuine early-phase human pharmacokinetic data showing it raises GH and IGF-1 — more than most compounds in this range can claim. What it does not have is outcome data: no large controlled trials demonstrating that the resulting GH elevation produces meaningful changes in body composition, recovery or healthspan in healthy adults.
The distinction between a demonstrated biomarker change and a demonstrated clinical benefit is the central caveat for this entire compound class.
The bottom line
A well-characterised mechanism with real pharmacokinetic data behind it, and no outcome trials. Untouched by the July 2026 hearing, so its regulatory position is unchanged and independent of that process.
Also in the Range
Sold within the CJC-1295 + Ipamorelin blend, which is how it is almost always used — the two act on separate receptors and are more effective paired than alone.